Biopharma Vision Into the Future— 20 Years?
Author Archives Cello Admin
Introducing Ken Garfinkel and Toni DeMola
The #metoo movement brought to light many other gender issues. In pharma:
External: In December 2017, JAMA published a study on industry payments to physicians, showing that male physicians received a greater number and higher value of industry payments (not including research funding) than female physicians, by a median difference of $1,470 annually.
Please join us in welcoming Tiffany Ahlers to Cello Health Advantage as Senior Vice President. Tiffany brings with her more than 20 years of experience in strategic marketing, market research, brand planning, and business development.
In mid-July, 2017, Advantage Healthcare joined Cello Health, the health-focused division of Cello Group plc, a UK-based publicly traded company. This move dramatically expands our reach and the type of work that we offer. Our new name is Cello Health Advantage.
We know that our president called together the top executives in the pharmaceutical industry just a few weeks ago. Although it is a bit hazy what exactly was discussed,1 a directive from our administration is that, for every new regulation passed, two should be repealed. It is not clear whether this topic was discussed at the meetings with the executives of our industry, and some have said that it may not apply to the FDA,2 but…
The biopharma industry has dramatically influenced the outcomes of many disease states, including but not limited to AIDS/HIV, hepatitis C, cancers, and many cardiovascular conditions. Despite such impacts, Simon and Garfunkel’s “Bridge Over Troubled Water” comes to mind in terms of the pharma industry in 2016.
Please join us in welcoming Tina Ghorban as the head of Oncology Advantage for Advantage Healthcare. Tina’s client-side expertise in market analytics, strategic positioning, and commercial assessments includes not only oncology and rare diseases, but also general medicine categories.
Precision medicine focuses on identifying which approaches will be effective for which patients, based on genetics, environment, and lifestyle. Is it what we have called “personalized medicine,” or perhaps you have called it “pharmacogenomics”? Precision medicine is the 2016 term.